In the first half of 2026, Chinese biotechnology firms leveraged historic cross-border licensing agreements to achieve profitability, yet global pharmaceutical giants indicate plans to curb business development budgets, raising questions about the sustainability of this funding model.
- Chinese biotech licensing deals hit a record US$110 billion in H1 2026
- Global drugmakers plan to tighten business development spending
- Licensing income surpasses IPOs as main funding source for Chinese biotech
What happened
Chinese biotechnology companies secured a record number of cross-border licensing agreements in the first half of 2026, topping US$110 billion and representing a significant increase compared to previous periods. These deals contributed to a major turnaround for several firms that had previously been loss-making, with companies like RemeGen, CSPC Innovation Pharmaceutical, and Suzhou Zelgen Biopharmaceuticals reporting notable profits due mainly to upfront payments and milestone fees from licensing arrangements with global pharmaceutical giants such as AbbVie and AstraZeneca.
Why it matters
The reliance of Chinese biotech companies on licensing deals with multinational corporations underscores the growing importance of global partnerships in sustaining innovation and development. At the same time, it highlights the cost-effectiveness of Chinese biotech assets relative to global peers, making them attractive acquisition targets even as pharma companies tighten their budgets.
However, caution from major drugmakers is emerging, with executives from companies like AstraZeneca and Pfizer signaling a slowdown in aggressive business development spending after extensive deals have already been made. This more selective approach may limit the volume or scale of future licensing agreements, casting uncertainty on how Chinese biotech firms will continue to fund their pipelines and convert innovation into commercial success.
What to watch next
Industry observers will closely monitor whether multinational drugmakers maintain or reduce their engagement with Chinese biotech firms, balancing cost-efficiency and selective spending strategies. Smaller licensing deals and acquisitions are expected to persist even if large-scale takeovers are less favored in the near term.
Further scrutiny will also focus on how Chinese firms adapt their financing approaches if licensing income starts to falter. This includes potential shifts back to the public markets or exploring alternative funding channels, as well as the pace at which Chinese biotechs continue generating high-quality clinical data that appeals to global partners.